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ABSTRACT (198/200)  
Protective immunity against Mycobacterium tuberculosis is poorly understood. The role of interleukin-4 
(IL-4), the archetypal T-helper-2 (Th2) cytokine, in the immunopathogenesis of human tuberculosis 
remains unclear. 
 
Blood and/or broncho-alveolar lavage fluid (BAL) were obtained from participants with pulmonary TB 
(TB; n=23) and presumed latent TB infection (LTBI; n=22). Messenger RNA expression levels of 
interferon-gamma (IFN-γ), IL-4, and its splice variant IL-4δ2 were determined by real-time PCR. The 
effect of human recombinant IL-4 (hrIL-4) on mycobacterial survival/ containment [colony-forming-units 
(CFU/ml] was evaluated in M. tuberculosis-infected macrophages co-cultured with mycobacterial 
antigen-primed effector T-cells. Regulatory T-cell (Treg) and Th1 cytokine levels were evaluated using 
flow cytometry. 
 
In blood, but not BAL, IL-4 mRNA levels (p=0.02) and the IL-4/IFN-γ ratio (p=0.01) was higher in TB 
versus LTBI. hrIL-4 reduced mycobacterial containment in infected macrophages (p<0.008) in a dose-
dependent manner and was associated with an increase in Tregs (p<0.001) but decreased CD4+Th1 
cytokine levels (CD4+IFN-γ+: p<0.001; CD4+TNFα+: p=0.01). Blocking IL-4 significantly neutralized 
mycobacterial containment (p=0.03), CD4+IFNγ+ levels (p=0.03) and Treg expression (p=0.03). 
 
IL-4 can subvert mycobacterial containment in human macrophages, likely via perturbations in Treg and 
Th1-linked pathways. These data may have implications in the design of effective TB vaccines and host-
directed therapies. 
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Take home message (248/256 characters) 
TB patients express high levels of IL-4 and exhibit a compartment-specific skewed Th2/Th1 response. In 
vitro, IL-4 subverts mycobacterial containment in M.tb-infected human macrophages indicating its 
potential utility as an immunotherapeutic target. 
 
INTRODUCTION  
Tuberculosis (TB) has killed over 1 billion people over the last two centuries and remains a 
major global public health threat today. Vaccination is the best hope for worldwide elimination 
of TB but most vaccine candidates are partially effective or ineffective [1]. More recently, there 
has been a profound interest in host-directed therapies as an adjunct to TB chemotherapy, either 
for shortening conventional treatment regimens, or to manage cases of programmatically 
incurable or difficult-to-treat drug-resistant TB [2]. However, novel strategies for the design of 
new vaccine candidates or immunotherapies will require a deeper understanding of the immune 
mechanisms underpinning susceptibility and disease progression, as these are currently not well 
understood.  
 
It has become central dogma that a surrogate of protective immunity against Mycobacterium 
tuberculosis (M.tb) is a robust Th1 response. Although, IFN-γ-related gene defects lead to 
increased susceptibility to TB [3, 4], patients with active TB have robust IFN-γ responses at the 
site of disease [5-7]. Furthermore, current vaccine candidates, including Bacille-Calmette-Guérin 
and MVA85A, prioritized based on their Th1-inducing ability, offer limited protection against 
TB in adults [8, 9].   
  
If a Th1 response alone cannot provide sufficient protection then what other factors, either alone 
or in tandem, underpin M.tb-specific protective host immunity?  Several innate and adaptive 
immune mechanisms have been postulated (reviewed in [10]). One possibility, supported by 
circumstantial evidence, is that M.tb induces a small but significant subversive Th2 response 
within a dominant Th1 environment, leading to bacterial proliferation and disease progression 
[11]. Indeed, murine [12] and cellular human data support this hypothesis; TB patients exhibit 
elevated IL-4 levels [6, 13, 14] correlating with immunopathology [6, 15], and IL-4 predicts 
progression to active disease in exposed healthcare workers [16] and household contacts [17]. 
Furthermore, the IL-4-receptor (IL4R) has been implicated in the development of TB-associated 
tissue pathology in both murine [18] and human TB [19]. Despite these findings, the role of IL-4 
in TB remains controversial due to discordant data and the technical challenges of measuring 
human IL-4 that is active at sub-ELISA concentrations (reviewed in [20]).  The existence of IL-
4δ2, an alternatively spliced variant and natural antagonist of IL-4 which is associated with 
protection in TB, further complicates the picture [6, 21, 22], and may explain why some studies 
failed to detect differences in IL-4 between TB patients and controls [23, 24]. Finally, whether 
IL-4 can subvert mycobacterial stasis/ killing in human cells has, hitherto, not been investigated.  
 
Thus, it is still unknown whether a Th2-like response is causally related to attenuated immunity, 
or, merely a consequence of excessive inflammation. To address these questions we interrogated 
Th2 responses in the peripheral blood and human lung, and further evaluated the effect of human 
recombinant IL-4 (hrIL-4) on mycobacterial survival in M.tb-infected human macrophages.  
 
 
METHODS  
Participant recruitment  
Newly diagnosed (<2 weeks of anti-TB therapy), drug-sensitive pulmonary TB (TB) patients 
were recruited from 4 primary care clinics in Cape Town. TB diagnosis was microbiologically 
confirmed by MGIT liquid culture. Presumed latently infected (LTBI) controls were 
asymptomatic with no clinical or radiological evidence of previous or current disease and were 
exposed persons (close contacts of TB index cases or healthcare workers) with a positive 
tuberculin skin test and interferon-gamma-release-assay (Quantiferon Gold-in-tube) result. 
Those with HIV co-infection or other chronic immunosuppressive diseases, and any known Th2-
associated conditions were excluded. Ethical approval was obtained from the University of Cape 
Town Research Ethics Committee. 
 
Peripheral blood and broncho-alveolar lavage sample processing 
After informed consent, 45-50ml of peripheral blood was collected by venipuncture into 
PAXgene RNA tubes (2.5ml; Qiagen) for RNA preservation and sodium heparin tubes (~42.5-
47.5ml) for peripheral blood mononuclear cell (PBMC) isolation. PBMCs were isolated by 
density centrifugation for use in downstream functional immunoassays. Broncho-alveolar lavage 
(BAL) was performed, as previously described [25]. Isolated BAL cells were stored in RNA 
stabilization buffer to fix the RNA profile. 
 
RNA extraction, reverse transcription and quantitative real-time PCR (qPCR) 
RNA was extracted from whole blood and BAL cells using the PAXgene blood RNA kit 
(Preanalytix) and RNeasy Plus kit (Qiagen), respectively. Following RNA quality assessment 
and reverse transcription, transcribed cDNA was amplified by qPCR using primers and probes 
specific to IFN-γ, IL-4 and IL-4δ2 (Table E1) from published literature [6]. Values were 
normalized to a validated reference gene, human acidic ribosomal protein (HuPO) [6]. Full 
methodological details are provided in the online data supplement. 
  
Expression, purification and bioactivity assessment of hrIL-4 
Human recombinant IL-4 (hrIL-4) protein was produced in a baculovirus-expression system and 
subsequently used in the mycobacterial containment assay. Full methods are provided in the 
online data supplement. 
 
Mycobacterial containment assay 
A mycobacterial (M.tb) containment assay was used to determine the effect of hrIL-4 on the 
ability of effector cells and macrophages to control the intracellular containment of M.tb within 
autologous monocyte-derived-macrophages (MDMs) using peripheral blood from active TB 
patients. MDMs were generated from PBMCs for 5 days, as previously described [26] followed 
by infection with H37Rv for 18 hours at an MOI of 3 [27]. Non-ingested bacteria were removed 
by washing. Frozen aliquots of H37Rv were randomly cultured to confirm the infecting bacterial 
dose. MDM viability was determined by trypan blue exclusion staining.  
Concurrent to MDM generation, PBMCs were also stimulated for 6 days with purified protein 
derivative (PPD;12μg/ml) with or without hrIL-4 to generate pre-primed effector T-cells (Teff 
cells). After 6 days, H37Rv-infected MDMs and Teff cells were co-cultured for 48 hours.  
Appropriate controls performed in duplicate included a reference control containing H37Rv-
infected MDMs only and a positive M.tb containment control containing H37Rv-infected MDMs 
co-cultured with PPD pre-primed effector T-cells (PPD Teff). The effect of IL-4 was assessed by 
adding various concentrations (5,20,100ng/ml) of hrIL-4 (day 1) together with PPD to PBMCs 
for 6 days to generate PPD+IL-4 Teff cells prior to co-culture with infected MDMs. After co-
culturing for 48 hours, intracellular H37Rv was released by lysis of infected MDMs and plated 
on Middlebrook 7H10 agar.  Colonies were counted and expressed as colony forming units per 
ml (CFU/ml).  In order to normalize the data to account for inter-patient variability, the  
 
 
percentage (%) M.tb containment was also reported, defined as the change in M.tb survival 
compared to the reference control (H37Rv-infected MDMs only; see Table E3 for experimental 
details): 
 
Cellular mechanisms associated with IL-4-mediated effect on M.tb containment 
Adherent (MDMs) and non-adherent (Teff cells) cellular fractions in the mycobacterial 
containment assay were analyzed by flow cytometry to determine the mechanisms contributing 
to the IL-4-modulation of M.tb containment. Adherent cells were lifted by treatment with cold 
0.5% EDTA and gentle scraping. Cells were stained using fluorescently-labeled antibodies 
against CD3, CD4, CD8, CD14, CD16, CD25, dendritic-cell-specific-intercellular-adhesion-
molecule-3-grabbing-non-integrin (DC-SIGN; a marker of alternative macrophage activation), 
Foxp3, IFN-γ, TNFα and IL-10 (BD Biosciences, Biolegend and eBiosciences). Cells were 
acquired on an LSRII flow cytometer and analyzed using FACSDiva software (BD Biosciences).  
 
Experimental condition (CFU/ml) 
Reference control (CFU/ml) 
___________________________  
 
100 -  x 100 =  % M.tb containment  
Neutralization of hrIL-4 
The effect of neutralizing IL-4 was assessed by adding anti-IL-4 antibody (20μg/ml; Abcam) to 
hrIL-4-containing interventions (day 1) in the mycobacterial containment assay. The effects on 
M.tb containment and associated cellular mechanisms were determined by colony counting 
(CFU/ml) and flow cytometry, respectively (Table E3 and E4). We also performed similar 
preliminary experiments to determine the effect of blocking the IL-4 receptor (IL-4R) using anti-
IL-4 receptor antibodies (10μg/ml, Abcam). 
 
Statistical analysis  
The Mann-Whitney U test was used to assess differences between participant groups and 
biological compartments.  Wilcoxon-matched pairs signed rank test was used to assess 
differences pre- and post-interventions. A p-value of <0.05 was considered significant. Statistical 
analyses were performed using GraphPad Prism version 6.0 (Graphpad). 
 
 
RESULTS 
Th1 and Th2 expression levels in the lungs and blood of TB patients and presumed LTBI 
controls 
mRNA levels were assessed using a validated qPCR assay (see online data supplement) in whole 
blood (WB) and BAL cells of TB patients (n=23 and 8, respectively) and presumed LTBI 
controls (n=22 and 7, respectively). IFN-γ expression levels (median [interquartile range, IQR]) 
per 10
6
 copies of HuPO) in BAL was ~6-fold higher compared to WB in both TB (6783 [2452-
24918] vs. 1721 [692-3161] copies, respectively; p=0.005) and LTBI (6281 [2570-10438] vs. 
1871 [1131-3521] copies, respectively; p=0.02, Figure 1a). IL-4 mRNA levels were higher in TB 
patients versus LTBI controls in WB (126 [45-232] vs. 42 [16-98] copies, respectively; p=0.02) 
but not in BAL cells (Figure 1b). Expression levels of IL-4δ2 were generally low and expression 
in some samples, particularly from BAL, were below the detection limit of the assay (Figure 1c). 
The IL-4/IFN-γ expression ratio, thought to represent the Th2/Th1 balance, was also higher in 
WB of TB patients compared to LTBI controls (0.046 [0.021-0.155] vs. 0.019 [0.010-0.036]; 
p=0.01) but not in BAL cells. The IL-4/IFN-γ ratio was much lower in BAL compared to WB in 
both groups (p<0.0001; Figure 1d). There were no inter-group or inter-compartment differences 
in the IL-4\IL-4δ2 ratio (Figure 1e). A similar compartment-specific pattern of IFN-γ and IL-4 
expression was observed  in matched BAL and blood samples in TB (n=5) and LTBI (n=4; 
Figure E4 in the online supplement) Additionally, no differences in IL-4 mRNA levels or the IL-
4/IFN-γ ratio were observed when stratified by smear grade, used as a proxy of disease extent, in 
the TB group (Figure E5). 
 
Soluble IL-4 protein, as measured by ELISA in TB antigen-driven cell culture supernatants 
levels were mostly below the detection limit of the assay in both BAL and blood (Figure E6). IL-
13 protein levels were detectable but also low, and there were no differences in expression levels 
between TB patients and LTBI controls (Figure E7). 
 
IL-4-primed effector cells can subvert mycobacterial containment  
In TB patients (n=8), the addition of PPD Teff cells to infected MDMs reduced the median M.tb 
CFU/ml from 30.7x10
3
 to 15.7x10
3
 compared to infected MDMs only (p=0.008; Figure 2a), 
equivalent to a 48% increase in M.tb containment (p=0.008; Figure 2b).  
 In the PPD+IL-4 Teff interventions, there was a significant increase in median CFU/ml at 5-
100ng/ml hrIL-4 (29.1x10
3
 to 43.8x10
3
; p=0.008; Figure 2a) compared to the PPD Teff control in 
TB patients (n=8). This equated to a decrease in % M.tb containment at each of the hrIL-4 
concentrations (1%, -73% and -33%, vs. 48% respectively; p=0.008; Figure 2b). The % M.tb 
containment was significantly lower at 100ng/ml compared to 5ng/ml hrIL-4 (p=0.008) 
indicating that the observed hrIL-4 effect was concentration-dependent.  
 
A similar trend was observed in LTBI participants (n=5) where the median CFU/ml increased in 
the PPD+IL-4 Teff interventions at 5-100ng/ml hrIL-4 (45.6x10
3 to 108.3x103) compared to the 
PPD Teff control (28.0x10
3
; Figure E10A). This resulted in decreased % M.tb containment at 
each hrIL-4 concentrations compared to the control (64%, 18% and -6%, vs. 72% respectively; 
Figure E10B). However, the differences between the PPD+IL-4 Teff interventions and PPD Teff 
control were not statistically significant (p=0.06).  Furthermore, there were no significant 
differences when equivalent wells were compared between the TB and LTBI groups (Table E5).  
 
IL-4 modulates the expression of regulatory T-cells (Tregs), Th1 cytokines and pattern 
recognition receptors (DC-SIGN) 
In order to determine the effect of hrIL-4 on cellular biomarker expression, cells (MDMs and Teff 
cells) were harvested from the mycobacterial containment assay and analyzed by flow 
cytometry.  
 
  
Regulatory T-cells (Tregs) 
The gating strategy for identification of Tregs (CD3
+CD4+CD25+FoxP3+) is shown in figure 3a. 
The median % Treg expression [IQR] was significantly increased in the PPD+IL-4 Teff 
intervention (100ng/ml hrIL-4; n=16) compared to the PPD Teff control (4.2% [1.2-10.5] vs. 
2.1% [1.1-4.2], p=0.0006; Figure 3b).  
 
Th1 cytokine and DC-SIGN expression 
The gating strategy for Th1 cytokine (IFN-γ and TNFα) and DC-SIGN expression in 
lymphocytes (CD3
+
CD4
+
 and CD3
+
CD8
+
) and macrophages (CD14
+
CD16
+
) is shown in Figure 
4a.  Median CD4
+IFN-γ+ expression at both 20 (n=8; 1.8% [0.4-4.1]) and 100ng/ml hrIL-4 
(n=16; 1.2% [0.7-3.8]), compared to the PPD Teff control (4.0% [1.2-7.4]), was significantly 
reduced (p=0.01 and p=0.0005, respectively; Figure 4b). Although IFN-γ expression was higher 
in the CD8
+ lymphocyte population, no significant differences were observed between the 
control and interventions.  
 
The effect of IL-4 on TNFα expression was less pronounced than CD4
+
IFN-γ expression. Lower 
median CD4
+
TNFα
+
 expression was observed in the PPD+IL-4 Teff intervention at 100ng/ml 
hrIL-4 compared to the PPD Teff control (1.4% [0.5-3.1] vs. 1.9% [0.9-6.7], respectively; p=0.02; 
Figure 4c). These differences were not observed in the CD8
+
 population. 
 
Macrophage (CD14+CD16+) DC-SIGN expression, a marker of alternative macrophage 
activation, was significantly reduced in the PPD Teff control compared to the infected MDMs 
only well (12.3% [4.6-21.2] vs. 23.8% [5.8-45.5] respectively, p=0.02). However, DC-SIGN 
expression increased in the PPD+IL-4 Teff intervention at 100ng/ml hrIL-4 (16.8% [5.8-21.5], 
p=0.02; Figure 4d).  
 
Neutralization of IL-4  
The effect of neutralizing rIL-4 was determined in TB patients (n=6).  Addition of anti-IL-4 
antibody (20μg/ml) to the PPD+IL-4 Teff intervention at 20ng/ml reduced the CFU/ml to levels 
similar to the PPD Teff control (76.5x10
3 to 32.4x103 CFU/ml, p=0.03; Figure 5a). Consequently, 
the % M.tb containment increased following the addition of anti-IL-4 antibodies (-20.0% to 
60.0%; p=0.03; Figure 5b). 
 
In terms of biomarker expression, anti-IL-4 (n=6; 20μg/ml) antibody was tested in the PPD+IL-4 
Teff intervention at 100ng/ml hrIL-4 only (limitations in sample amount prevented testing of 20 
ng/ml hrIL4). Following the addition of antibody, Treg frequency (0.8% [0.8-1.8] to 0.2% [0.2-
0.8], p=0.03; Figure 5c) and CD4
+
IFN-γ
+ 
expression (2.0% [1.4-2.5] to 2.9% [2.1-5.2], p=0.03; 
Figure 5d) reverted to levels similar to that of the PPD Teff control. No significant effect on 
TNFα and DC-SIGN expression were observed (data not shown). 
 
The addition of anti-IL-4R antibody produced a similar pattern on mycobacterial containment 
(n=2) Treg frequency (n=4) and CD4+IFN-γ+ expression (n=4) but no significant differences 
were observed when compared to wells with no anti-IL-4R antibody added (Figure E12 in the 
online supplement). 
 
  
DISCUSSION 
The key findings of this study were that: (i) in blood, but not BAL, TB patients exhibited higher 
IL-4 mRNA expression and a higher IL4/IFN-γ ratio compared to LTBI controls; (ii) overall, IL-
4δ2 expression levels were very low; (iii) responses were compartmentalized (higher IFN-γ, 
lower IL-4, and a lower IL4/IFN-γ ratio in the lungs versus blood) in both TB patients and LTBI 
controls; (iv) hrIL-4 can subvert M.tb containment in human macrophages, and these effects 
were concentration-dependent; (v) IL-4-driven mycobacterial containment was  associated with 
an increased Treg frequency, reduced CD4+Th1 cytokine expression, and increased macrophage 
DC-SIGN expression, and (vi) these effects were reversed upon neutralization of IL-4 using anti-
IL-4 antibody. 
 
This is the first study to demonstrate that IL-4 can directly impact mycobacterial containment in 
M.tb-infected human macrophages. What could be driving a Th2 response leading to disease 
progression? Evidence suggests that both the pathogen and environmental factors may be 
involved [28].  For example, certain bacterial components, such as ManLAM, can stimulate IL-4 
production [29] and exposure to environmental mycobacteria or helminths can also drive/ 
facilitate a mixed Th2/Th1 response [11, 30]. The latter, which is common in developing 
countries, is thought to contribute to the failure of BCG in these areas [11]. 
 
What are the implications of these findings? Our data suggest that vaccines, whether 
prophylactic or therapeutic, should be designed to include antigens that not only induce Th1 
immunity but also downregulate Th2 or immunoregulatory responses (for example, M. vaccae 
[31] and hps65 DNA [32] both induce strong Th1 and cytotoxic T-cell responses, but 
simultaneously downregulate a Th2 response, and have shown some therapeutic efficacy in 
preclinical studies [33] and are now being evaluated in a phase 3 trial [34]). Host-directed 
therapies also exhibit tremendous potential, either to shorten treatment regimens or expand the 
limited treatment options available for those with highly drug-resistant TB [2, 35]. Interestingly, 
dupilimab, a monoclonal antibody against the IL-4-receptor-α chain, which has been approved 
for use in atopic dermatitis [36], is currently being evaluated for the treatment of persistent 
asthma [37]. It is intriguing to speculate that such an agent might have utility as an 
immunotherapeutic agent in TB; further in vitro studies are warranted.  
 
Our findings of increased IL-4 in the peripheral blood of TB patients are consistent with other 
reports [6, 14, 22, 38]. Conversely, some studies failed to show differences in IL-4 levels [23, 
24].  Measuring IL-4 can be challenging (reviewed in [20]) and many studies failed to 
distinguish between IL-4 and IL-4δ2, which can have significant effects on study conclusions 
[22]).  This is the first study to investigate IL-4δ2 levels in both the lung and peripheral blood 
compartments in a TB-endemic setting. Observations on the protective effect of IL-4δ2, in 
relation to IL-4, in TB have been discussed elsewhere [11]. Previous studies focused on 
peripheral blood [14, 22, 38] and only one UK-based study measured compartmental differences 
in IL-4δ2 expression [6]. These studies found either increased levels [6] or no difference in 
expression between patients and controls [14, 38]. Our results are consistent with the latter. Low 
IL4δ2 expression observed in our and other studies is not surprising given the decreased stability 
of IL-4δ2 mRNA [39] and that splice variant expression can be as little as 15% of the parent 
cytokine [40]. Evidence suggests that IL-4δ2 protein is antagonistic to IL-4 and acts like a Th1 
cytokine in in vitro culture [41] but further mechanistic studies are required to elucidate its exact 
role during TB infection. 
 Measurement of TB antigen-specific Th2 protein (IL-4 and IL-13) levels in cell culture 
supernatants revealed no differences in expression between the different compartments or study 
groups (Figures E6 and E7 in the online supplement). IL-4 protein levels were mostly below the 
detection limit of the assay which highlights the difficulties in measuring this low expressing 
cytokine. Like IL-4, IL-13 has been implicated in the development of TB-associated lung 
pathology in both mice and humans [18, 19]. Although IL-13 and IL-4 share common receptors 
and signaling pathways, they can have distinct expression profiles and functions in Th2-driven 
conditions [42], but whether this is also true in TB requires further investigation. This lack of 
concordance between IL-4 mRNA and IL-13 protein levels observed in our study could be due to 
these intrinsic differences in expression [42], differences in the abundance and profile of mRNA 
transcript expression compared to protein secretion [43], and/or recall responses to TB-antigen 
stimulation compared to direct ex vivo measurement. “ 
 
The use of IL-4 and/or IL4δ2 as a biomarker of TB progression or treatment response may have 
some diagnostic utility but will require large validation studies. However, several technical 
challenges related to the biological properties of IL-4 and IL4δ2 are likely to hinder the 
development of an antibody-based diagnostic assay. These include sub-ELISA expression levels 
([44, 45] and Figure E6), rapid degradation [46] and reduced bioavailability [47, 48] of IL-4 
protein, and lack of commercial antibodies that can distinguish between the two isoforms. 
Furthermore, detection of the IL4δ2 protein has only been described in asthma [49] but its 
mechanism of action and precise function remains unclear. 
 
The differential expression of IFN-γ and IL-4 in the lungs compared to peripheral blood suggests 
a compartment-specific pattern of cytokine expression and cellular trafficking, which may reflect 
the active recruitment and clonal expansion of IFN-γ-producing T-cells at the site of disease [50] 
subsequently allowing for a greater expansion of IL-4-producing Th2 cells in the peripheral 
blood.  
 
In TB patients, a ~50% reduction in M.tb survival in infected MDMs by PPD pre-primed 
effectors (PPD Teff control) is similar to the magnitude of containment previously described in 
the context of Treg effects [25]. Addition of IL-4 lead to a reduction in M.tb containment by 50-
120%. The addition of IL-4 to un-primed T-cells before commitment to a specific T-cell lineage, 
creates a Th2-polarizing microenvironment where IFN-γ expression and Th1 differentiation 
pathways are inhibited [51]. The IL-4-concentration-dependent effect observed in this 
intervention suggests that there is some level of competition between PPD-driven Th1 and IL-4-
driven Th2 polarization.  
 
A similar reduction in mycobacterial containment was also observed in LTBI participants but 
this failed to reach statistical significance (p=0.06) likely because there were fewer sample 
numbers in this group. Furthermore, no differences were observed when TB and LTBI groups 
were directly compared (Table E5). This suggests that the effect of IL-4 in our model was not 
restricted to any specific clinical phenotype and similar cellular mechanisms were induced by IL-
4 in both groups leading to the observed reduction in containment. 
 
Our data indicate simultaneous expansion of the Treg population and subsequent downregulation 
of a Th1 response. While IL-4 has been implicated in the development [52] and maintenance of 
Tregs [53], the data are conflicting and this relationship has never been demonstrated in the 
context of human TB.  There is substantial evidence on the detrimental role of Tregs in drug-
sensitive TB [25, 54-56], drug-resistant TB [26, 57], and TB/HIV co-infection [58], including 
attenuation of mycobacterial containment in vitro [25, 26], and downregulating Th1 responses 
[25, 56]. There is substantial evidence on the detrimental role of Tregs in TB [25, 26, 56] 
including attenuation of mycobacterial containment in vitro [25, 26], and downregulating Th1 
responses [25, 56]. The Treg-mediated effect on Th1 responses in our model seem to be 
restricted to the CD4 T-cell population (the most important IFN-γ producing cells involved in 
controlling M.tb replication [59]). Although producing very little IL-10 (Table E6), these Tregs 
may exert their regulatory effects by other cellular mechanisms (reviewed in [60]). Further 
investigation is required to elucidate these mechanisms.  
 
DC-SIGN expression on macrophages was also increased in the PPD+IL-4 Teff intervention. DC-
SIGN facilitates entry of M.tb into phagocytic cells and is a hallmark of alternatively-activated 
M2 macrophages. A number of M.tb components that act via DC-SIGN can drive host 
immunoregulatory mechanisms [61]. In our model, M2 polarization is likely occurring as both 
IL-4 [11] and FoxP3
+
 Tregs [62] can drive alternative macrophage activation. M2 macrophages 
also have anti-mycobactercidal properties [11] and may be contributing to the observed reduction 
in M.tb containment. 
 
Preliminary experiments indicate that blocking of the IL-4 receptor resulted in a similar effect to 
neutralization of IL-4 on mycobacterial containment, Treg frequency and IFN-γ expression 
although no significant differences were observed likely due to the limited sample numbers. 
Previous evidence indicates that IL4Rα-mediated signalling is associated with tissue pathology 
in TB-infected mice [18] and the development of necrotizing granulomas in human TB [19]. 
However, further investigations are needed to determine the precise downstream mechanisms 
that may be driving this effect.  
 
There are a number of limitations to our study: (i) The hrIL-4 concentrations used in the M.tb 
containment assays may, in some cases, have been higher than that encountered physiologically 
in human tissue (as low as picogram levels). However, there are a number of factors 
overestimating the concentration of active recombinant IL-4 protein in experimental conditions 
(for example, (a) recombinant proteins tend to be less stable and active compared to their 
naturally produced counterparts [63], (b) mechanisms such as chaperone proteins [64] and 
soluble IL-4 receptors [65] can prolong stability and increase IL-4 bioactivity but are normally 
absent in an in vitro system, (c) proteins expressed in insect cell systems may undergo 
inappropriate N-glycosylation patterns which can affect protein function and stability [64], and 
(d) quantification methods, including the Bradford assay, fail to distinguish between functional 
and non-functional recombinant protein). Moreover, the rIL-4 concentrations used in our M.tb 
containment assays were derived from those used in the 
3
H-thymidine T-cell proliferation assay 
(Figure E9C) that produced a significant effect,  and other in vitro stimulation experiments have 
used similar IL-4 concentrations [66]. (ii) We did not use alveolar macrophages in the stasis/ 
containment experiments. It was difficult to obtain sufficient BAL cell numbers to perform all 
the required experiments given the safety and logistical limitations of the bronchoscopy 
procedure (~200 ml of instilled saline), and similar outcomes were obtained either using MDMs 
or alveolar macrophages in another M.tb containment assay [25] (iii) We only performed 
preliminary functional experiments to determine the effect of IL-4R on M.tb containment and 
selected cellular mechanisms and did not specifically target mechanisms within the signalling 
pathway. The aim of the study was to determine the ultimate effect of IL-4 on mechanisms 
known to be associated with TB, including Tregs, the Th1 response and alternative macrophage 
activation (discussed in [11]). Future studies are required to probe the effects of blocking specific 
molecules within the IL-4 signalling pathway such as STAT-6, IRS-1 and GATA-3 to determine 
their effects on M.tb containment. (iv) We were only able to measure mRNA expression levels in 
a limited number of matched BAL and blood samples from TB patients (n=5) and LTBI controls 
(n=4) either because blood was not collected prior to the bronchoscopy procedure, or samples 
were excluded due to poor RNA quality or low yield. However, the matched samples (Figure E4 
in the online supplement) also showed a compartment-specific effect similar to the complete data 
set outlined in Figure 1 (characterized by elevated IFN-γ levels were in the lungs whereas IL-4 
levels were increased in the peripheral blood).  
 
In conclusion, IL-4 subverted anti-mycobactericidal mechanisms and undermined M.tb 
containment in infected monocyte-derived-macrophages. These data inform the development of 
vaccines and immunotherapeutic interventions against M.tb.  
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FIGURES LEGENDS 
Figure 1. mRNA expression levels of a) IFN-γ b) IL-4 and c) IL-4δ2  and cytokine expression ratios 
of d) IL-4\IFN-γ and  e) IL-4\IL-4δ2 in cells of broncho-alveolar lavage (BAL) and peripheral whole 
blood (Blood) from patients with pulmonary tuberculosis (TB; BAL n=8; blood n=23) and 
presumed latently infected controls (LTBI; BAL=7; blood n=22) measured using a validated 
quantitative real-time PCR assay. Data is shown on a log10 scale and copy numbers are expressed per 
million copies of HuPO (validated reference gene). Statistical analyses between groups were performed 
using the Mann-Whitney test and p<0.05 was deemed significant.  
 
Figure 2. The effect of human recombinant IL-4 on mycobacterial containment in infected 
monocyte-derived macrophages (MDMs) from pulmonary tuberculosis patients (TB; n=8)). A 
mycobacterial containment assay was performed where H37Rv-infected MDMs were cultured by 
themselves or co-cultured with peripheral blood mononuclear cells pre-primed with purified protein 
derivation alone (PPD Teff), or PPD and hrIL-4 (PPD+IL-4 Teff)at concentrations of 5, 20 and 100ng/ml 
hrIL-4. Results are expressed as a) median colony forming units (CFU/ml) in TB patients and b) The % 
mycobacterial (M.tb) containment, defined as the change in M.tb survival compared to the “H37Rv-
infected MDMs only” control, were also determined. Increased % M.tb containment indicates a reduction 
in M.tb survival whereas decreased % M.tb containment indicates an increase in M.tb survival. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and p<0.05 was deemed 
significant. 
 
Figure 3. The effect of human recombinant IL-4 on regulatory T-cell (Treg) expression in a 
mycobacterial containment co-culture assay as measured by flow cytometry. a) The flow cytometry 
gating strategy for identification of Tregs (CD3+CD4+CD25+FoxP3+) within the lymphocyte population 
and b) the frequency (%) of Tregs in the co-cultured lymphocyte population of the mycobacterial 
containment assay in pulmonary TB patients. H37Rv-infected MDMs were co-cultured with peripheral 
blood mononuclear cells pre-primed with PPD alone (PPD Teff), or PPD and hrIL-4 (PPD+IL-4 Teff) at 
concentrations of 20ng/ml (n=10) and 100ng/ml (n=16) hrIL-4. Tregs were expressed as a % of CD4+ 
lymphocytes. Statistical analysis was performed using the Wilcoxon matched-pairs signed rank test and 
p<0.05 was deemed significant.  
 
Figure 4. The effect of human recombinant IL-4 on Th1 cytokine expression in lymphocytes and 
DC-SIGN expression in macrophages in a mycobacterial containment assay as measured by flow 
cytometry. a) The flow cytometry gating strategy for identifying IFN-γ and TNFα within the lymphocyte 
(CD4+ and CD8+) population and DC-SIGN expression within the macrophage (CD14+CD16+) 
population. The % of CD4+ and CD8+ lymphocytes expressing b) IFN-γ, c) TNFα and CD14+CD16+ 
macrophages expressing d) DC-SIGN in cells harvested from a mycobacterial containment assay from 
pulmonary TB patients. H37Rv-infected MDMs were co-cultured with peripheral blood mononuclear 
cells pre-primed with PPD alone (PPD Teff), or PPD and hrIL-4 (PPD+IL-4 Teff) at concentrations of 
20ng/ml (n=10) and 100ng/ml (n=16) hrIL-4. Statistical analyses were performed using the Wilcoxon 
matched-pairs signed rank test between interventions and the Mann Whitney U test between CD4+ and 
CD8+ lymphocytes. A p-value<0.05 was deemed significant.  
 
Figure 5. The effect of neutralizing human recombinant IL-4 on mycobacterial containment and on 
cytokine and regulatory T-cell expression in a mycobacterial containment assay. H37Rv-infected 
MDMs were co-cultured with peripheral blood mononuclear cells pre-primed with PPD alone (PPD Teff) 
or PPD and hrIL-4 (PPD+IL-4 Teff) at 20 and 100ng/ml hrIL-4. To the IL-4 interventions, anti-IL4 
antibody (20μg/ml) was added at the same time as hrIL-4 (day 1). In TB patients (n=6), mycobacterial 
containment was measured in terms of a) colony forming unit/ml (CFU/ml) and b) % mycobacterial 
(M.tb) containment, defined as the change in M.tb survival compared to the “H37Rv-infected MDMs 
only” control.  Increased % M.tb containment indicates a reduction M.tb survival whereas decreased % 
M.tb containment indicates an increase in M.tb survival. The % of CD4+ lymphocytes that were c) Treg 
(CD25+FoxP3+) and expressing d) IFN-γ were also determined within the system (cells co-cultured within 
the M.tb containment assay) by flow cytometry. In this case, IL-4 neutralisation was assessed using anti-
IL-4 (n=6). Statistical analysis was performed using the Wilcoxon matched-pairs signed rank test and 
p<0.05 was deemed significant. 
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IL-4 subverts mycobacterial containment in M. tuberculosis-infected human 
macrophages 
 
ONLINE DATA SUPPLEMENT 
 
Anil Pooran
1
, Malika Davids
1
, Andrew Nel
2
, Aubrey Shoko
3
, Jonathan Blackburn
2
, Keertan 
Dheda
1,4 
 
1Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Cape Town, 
Cape Town, South Africa.  
2Department of Integrative Biomedical Sciences; Institute for Infectious Disease and Molecular Medicine, 
University of Cape Town, Cape Town, South Africa 
3Centre for Proteomics and Genomics Research, Cape Town, South Africa 
4Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School 
of Hygiene and Tropical Medicine, London, UK 
 
 
 
 
 
 
 
 
 
METHODS 
Quantitative real-time polymerase chain reaction (qPCR) 
Choice of primers, hydrolysis probes and amplification targets used for quantitative PCR  
The primer and hydrolysis probes sequences were taken from published sequences in the 
literature (1,2) and are shown in Table E1. The primers were designed to span exon-exon 
boundaries so as not to amplify genomic DNA and thus increase assay specificity. Furthermore, 
the design of intro-spanning primers was an absolute requirement to differentiate between the IL-
4 and IL-4δ2 transcripts. Primers and probes were synthesized by IDT (Integrated DNA 
Technologies Ltd.) on a scale of 25nM and 100nM, respectively. Primers were purified by 
standard desalting whereas probes underwent HPLC purification. A fluorophore (FAM) and two 
fluorescent quencher (FQ) molecules (an internal ZEN FQ and IOWA BLACK FQ at 3’-end) 
were incorporated into the hydrolysis probes. Primer sequence specificity was confirmed by melt 
curve analysis on the Rotor-Gene Q (Qiagen) using the Rotor-Gene SYBER Green PCR kit 
(Qiagen) assay, according to the manufacturer’s instructions.  
 
RNA extraction and assessment of RNA quality 
RNA was extracted from whole blood and BAL cells using the PreAnalytiX PAXgene Blood 
RNA kit (Qiagen) and RNeasy Plus Mini Kit (Qiagen), respectively. Genomic DNA was 
removed in each case by DNase I treatment and use of a gDNA eliminator column, respectively. 
All standard protocols for cleaning, handling and storage during RNA isolation procedures were 
strictly followed. Quality and quantity assessment of isolated RNA was performed on an Agilent 
Bioanalyzer 2100 (Agilent) using the Agilent RNA 6000 Nano kit. Total RNA obtained ranged 
from 0.5-5μg. Samples were only used in reverse transcription reactions if an RNA Integrity 
Number (RIN) of ≥7.5 was obtained. 
 
Reverse transcription and qPCR amplification 
The iScript cDNA synthesis kit (BioRad) was used to convert RNA samples to cDNA. The kit 
uses a modified MMLV-derived RNase H+ transcriptase. RNA quantity limited the amount of 
input RNA to 500ng per reaction. A 20μl reaction was set up containing 500ng of sample RNA, 
reverse transcriptase, nuclease free water and iScript mastermix (containing a proprietary 
mixture of oligo (dT), random hexamers and RNase inhibitor). The reaction was performed in a 
G-Storm thermal cycler (G-Storm) using following conditions: 5 minutes at 25ºC; 30 minutes at 
42ºC; 5 minutes at 85ºC.  Appropriate control reactions containing no reverse transcriptase 
enzyme were also included. 
 
Amplification of cDNA was performed on a Rotor-Gene Q real-time PCR machine (Qiagen). 
Reactions were set up manually using the Rotor-Gene probe PCR kit. The 2x Rotor-Gene probe 
PCR Master Mix contained HotStar Taq Plus DNA Polymerase, dNTP mix and Rotor-Gene 
Probe PCR buffer (containing a proprietary mixture of Tris-Cl, KCl, NH4Cl, MgCl2 and Q-
Bond). Primers were used at pre-validated concentrations of 500nM for HuPO and IFN-γ and 
250nM for IL-4 and IL-4δ2. Probes were used at concentrations of 250nM for all analytes, as 
previously described (1). 2μl of sample cDNA and 5μl of 10-fold serial dilutions of linearized 
plasmid standards (described below) were added to the appropriate sample and standard tubes, 
respectively. The final PCR reaction volume was 20μl. The amplification conditions were as 
follows: initial step of 95°C for 10 minutes, followed by 40 cycles of 95°C for 10 seconds and 
60°C for 30 seconds. Standards were run in triplicate and samples were run in duplicate. 
Appropriate no template controls (NTC) and no reverse transcriptase controls were includes in 
each qPCR run. 
 
Method of mRNA quantification  
Absolute quantification, where the mRNA copy number in a sample is expressed in relation to a 
standard curve containing known numbers of nucleic acid copies, was chosen as the method of 
mRNA quantification. It allows for greater control of inter-assay variation in PCR efficiency and 
experimental reproducibility. This is beneficial especially when large sample numbers are 
assayed over a period of time from different study sites (3). As such, an external standard curve 
using recombinant DNA inserted into a plasmid was chosen because of its long term stability, 
high reproducibility and its ability to more appropriately mimic the length of native mRNA. 
Furthermore, it shows higher sensitivity compared to recombinant RNA standards (4). 
 
Generation of cDNA targets of interest 
Peripheral blood mononuclear cells (PBMCs) from a healthy control were isolated and 1x10
6
 
cells were stimulated for 16 hours with 10μg/ml of phytohaemmaglutinin (PHA) in a 96-well 
round bottom plate. Total RNA was extracted and reverse transcribed using 1μg of RNA. cDNA 
was amplified using the Kappa Taq PCR kit (Kappa Biosystems) and cloning primers (Table E2) 
according to the manufacturer’s instructions. The cloning primers were designed to amplify a 
region of the cDNA containing the target qPCR sequence for IFN-γ and HuPO. The PCR 
reaction conditions were as follows: initial step of 95°C for 2 minutes, followed by 30 cycles of 
95°C for 1 minute 30 seconds, 50°C for 1 minute, 72°C for 1 minute and a final extension step of 
72°C for 10 minutes. The amplified PCR product was run on a 1% Agarose gel at 200V for 1 
hour. The bands of interest were excised and purified using Zymoclean Gel DNA Recovery Kit 
(Zymo Research). pGEM-T Easy (Promega) plasmids containing IL-4 and IL-4δ2 cDNA were 
generated during cloning procedures to express recombinant IL-4 protein (described below). 
 
Sub-cloning of cDNA into pGEM-T Easy plasmid 
Purified cDNA was ligated into the pGEM-T Easy plasmid (Promega) at a vector:insert ratio of 
3:1, transformed in JM109 chemically competent E. coli cells (Promega) and purified using the 
GeneJet Plasmid Miniprep kit (Thermo Scientific), according to the manufacturer’s instructions. 
Plasmids were sequenced by Inqaba Biotech Ltd using an ABI 3500XL DNA sequencer to 
confirm the successful insertion of the target DNA into the plasmid.  
 
Linearization and serial dilutions of the plasmid standards 
The HuPO, IFN-γ, IL-4 and IL-4δ2 plasmids were linearized using SacI FastDigest enzyme 
(Thermo Scientific), according to the manufacturer’s instructions. The plasmids were linearized 
because circular plasmid standards tend to overestimate copy numbers and reduce PCR 
efficiency (5). Each plasmid was identified to have a single SacI restriction site outside the target 
cDNA sequence. Linearized plasmid concentrations were re-measured and the exact copy 
number per tube was determined using the following formula: 
 
 
 
10-fold serial dilutions containing down to 10
1
 copies were made in nuclease-free H2O and 
added to appropriate PCR tubes (Qiagen) for qPCR amplification reactions. 
 
Data Analysis and Normalization strategy 
Data analysis was performed using the Rotor-Gene Q series software 2.0 (Qiagen). The cycle 
threshold (Ct) was automatically determined by the software for each qPCR run. Samples that 
were not reproducible (technical replicates with variations in Ct values >0.5 were considered 
outliers) or that were below the detection limit of the assay were given an arbitrary value of 1 
copy in the final analysis, as previously described (1). Copy numbers were normalized using 
human ribosomal protein (HuPO) as a reference gene. The suitability of HuPO as a reference 
gene in pulmonary tuberculosis gene expression studies has been pre-validated (6) and used in 
similar study settings(2,7). Gene of interest copy numbers are expressed per million copies of 
HuPO. Coefficient of variance was used to assess inter- and intra-assay variation.  
 
Soluble protein levels of IL-4 and IL-13 in TB antigen driven cell culture supernatants 
BAL cells and PBMCs were seeded in 96-well round bottom plates at a concentration of 1x10
6
 
/ml and stimulated with the M.tb-specific antigens ESAT-6 and CFP-10 (Oxford Immunotec) 
using manufacturer recommended concentrations (which are proprietary and cannot be 
disclosed) for 5 days. Supernatants were harvested and measured by ELISA (IL-4; eBiosciences) 
or Luminex multiplex assay (IL-13; Millipore) according to the manufacturer’s instructions. 
 
Expression and purification of human recombinant IL-4 (hrIL-4) 
Human recombinant IL-4 (hrIL-4) was expressed in a baculovirus insect cell system, using a 
method described in (8). Full length human IL-4 cDNA (Accession number: NM_000589.2) was 
purchased from Origene (Origene Technologies) and subsequently cloned into an in-house 
baculovirus transfer vector (8) designated pAP01 (sequence provided at the end of the online 
supplement) using BamH1 and AvrII restriction enzymes (Thermo Scientific). A decahistidine 
(His) tag was inserted downstream of the IL-4 sequence using specific primers to facilitate 
protein purification. The IL-4-His cDNA from the newly designated pAP01-IL4-His vector 
construct was transferred to linearized bacmid viral DNA (pBAC10:KO1629) by co-transfection 
into Spodoptera frugiperda (Sf21) cells using lipofectin (Sigma-Aldrich). Virus-containing cell 
supernatants were used in several rounds of viral amplification to generate high-titre viral stocks 
(10
7
-10
8
 plaque forming units/ml), as measured by quantitative real-time PCR, for large-volume 
protein expression. Initial small-scale expression studies were performed to determine the 
optimal multiplicity of infection (MOI) and the time-to-harvest post-infection (PI). Cell 
morphology and viability were periodically assessed by trypan blue exclusion staining and 
examination under a microscope to confirm infection of cells. Large-scale IL-4 expression was 
performed at 28
o
C in a 500ml culture of Sf21 cells (1.5x10
6
/ml in Insect Xpress media (Lonza) 
supplemented with 2% fetal bovine serum (Lonza)) infected at an MOI of 10 and harvested 72 
hours PI. hrIL-4 was purified from the virus-infected cell culture supernatants, supplemented 
with  1% Benzonase (Novagen) and 1x EDTA-free protease inhibitor cocktail (Roche), by Ni
2+
-
NTA affinity purification using the His spin miniprep kit (Zymo Research). Protein identity was 
determined by sodium-dodecyl-sulfate-polyacrylamide-gel-electrophoresis (SDS-PAGE) and 
Western blot using IL-4-specific HRP-conjugated antibody (Abcam). Protein concentration was 
determined by Bradford assay (Sigma-Aldrich).  
 Assessment of hrIL-4 bioactivity 
T-cell proliferation 
The effect of hrIL-4 on T-cell proliferation was assessed by 
3
H thymidine incorporation assay. 
5x104 PBMCs were stimulated with anti-CD3 antibody (eBiosciences) for 3 days at 37oC and 5% 
CO2, followed by the addition of hrIL-4 (5, 20 and 100ng/ml) alone or together with anti-IL4 
antibody (0.5, 5 and 20μg/ml; Abcam). Cells were incubated for a further 3 days followed by the 
addition of 1μCi of 3H-Thymidine (AEC Amersham) to each well for 18 hours. The cells were 
harvested and counted by liquid scintillation spectrophotometry. The mean counts per minute 
(CPM) for each condition was used to calculate the % proliferation, as shown below: 
 
 
 
 
CD23 expression in B cells 
Flow cytometry was used to determine the effect of hrIL-4 on CD23 expression in B cells. 
PBMCs at 1.5x10
6
 per well in a 24-well plate were stimulated with various concentrations of 
hrIL-4 (0.5-50ng/ml) for 3 days at 37
o
C and 5% CO2. Cells were harvested and stained with 
fluorescently labeled antibodies against CD3, CD19 and CD23 (eBiosciences). Cells were 
acquired on an LSRII flow cytometer and analysed using FACSDiva software (BD Biosciences).  
 
Mean CPM of hrIL4 intervention -  
Mean CPM of negative control 
Mean CPM of negative control 
_____________________________  
 
x 100 =  % Proliferation 
Mycobacterial containment assay 
Preparation of H37Rv stocks 
H37Rv (donated by State Laboratory) was grown in Middlebrook 7H9 broth (Difco) 
supplemented with 10 % OADC (oleate-albumin-dextrose-catalase) enrichment media (BD 
Biosciences) and 0.02% glycerol (Merck). Cultures were grown in a tissue culture flask 
(Corning) at 37°C and 5% CO2 in a humidified incubator and shaken daily. Growth was assessed 
periodically until cultures reached mid-log phase. 1ml aliquots of culture were then snap frozen 
in 10% glycerol using liquid nitrogen and stored at -80°C. 
 
Colony forming units (CFU)/ml, were determined using three randomly selected frozen H37Rv 
tubes. The bacterial suspension was homogenised by aspiration using a 1ml insulin syringe. 10-
fold serial dilutions were made from the stock and the three lowest dilutions (10
2
, 10
1
, 10
0
 CFUs) 
were plated in replicates of 6 onto Middlebrook 7H10 gridded agar plates (BD Biosciences) 
supplemented with 10% OADC. Plates were incubated in a 37
o
C oven for 10-16 days or until 
visible colonies were formed. Colonies were counted using an inverted microscope and the 
CFU/ml for each tube was calculated using the flowing formula: 
 
 
 
Immunofluorescence staining  
Cells were harvested into 15x75mm 5ml polystyrene tubes (BD Biosciences), washed in 2ml 
FACS buffer (0.01% sodium azide, 10% human AB serum, 1xPBS) and centrifuged at 1200rpm 
for 5 minutes. The supernatants were removed and the cell pellet was resuspended in 100ul of 
FACS buffer. Appropriate fluorescently conjugated antibodies for cell surface markers were 
added at previously titrated volumes to the cells and incubated in the dark for 15 minutes at room 
temperature. Cells were then washed to remove unbound antibodies and fixed in 100μl of BD 
Cell Fix diluted 1:10 in H2O (BD Biosciences) for 15 minutes in the dark. After another wash 
step, cells were permeabilized in 500ul PERM II solution diluted 1:10 (BD Biosciences) for 10 
minutes in the dark. Fixation and permeabilization was performed using Human FoxP3 buffer set 
(BD Biosciences) for Treg staining. Appropriate fluorescently conjugated antibodies for 
intracellular markers was added to each tube at previously titrated volumes and incubated for 30 
minutes in the dark. The cells were then washed to remove unbound antibodies and 100ul of 4% 
paraformaldehyde solution was added to each tube for at least 30 minutes.  
 
RESULTS 
Validation of qPCR assay 
Primer specificity was confirmed by melt curve analysis (Figure E1). qPCR assay validation was 
performed on plasmid standards prior to analysis of samples. The limit of detection of the assay 
was determined to be 10 copies as the replicate Ct values below 10 copies were very variable 
(difference in Ct replicates >0.5). In most experiments, PCR efficiency approached 100% and R
2 
value was >0.99. No transcripts were detectable in the ‘no template’ controls (NTC) or in the ‘no 
reverse transcriptase’ controls (no RT controls) indicating a lack of genomic DNA 
contamination. The coefficient of variance between technical replicates within a single assay 
(intra-assay variation) was <~20% at each concentration. Figure E2 shows an example of IL-4 
copy number determination by absolute quantification in a validated qPCR assay. PCR 
efficiency, copy numbers and Ct values were measured in 5 separate experiments and compared 
in order to assess inter-assay variation. The mean PCR efficiency was 100% (95% CI; 96.1-
103.9) and the coefficient of variance at each dilution was <10% (Figure E3A). Inter-assay 
variations in Ct values are shown in figure E3B. 
 
Expression, identify confirmation and bioactivity of hrIL-4 
The full nucleotide sequence of the transfer vector pAP01-IL4-His containing IL-4 used for co-
transfection with bacmid DNA is shown in figure E4. The presence of the IL-4-His cDNA 
construct following transfection was determined by PCR amplification of P0 viral DNA and 
visualization of the amplified inserts by agarose gel electrophoresis. In the large-volume protein 
expression harvested at 3 days PI, cells were elongated and enlarged at ~50-60% viability 
indicating viral infection of cells. hrIL-4 protein yield from a 500ml culture ranged between 60-
120μg. Analysis of the hrIL-4 protein purification fractions by SDS-PAGE indicated the 
presence of 2 bands at ~19kDa and ~17kDa in the purified and concentrated fraction (Figure 
E5A). The expected size of His-tagged rIL-4 is ~17-18kDa and these two bands could represent 
different glycosylated forms of IL-4, which has also been shown to occur in baculovirus 
expressed swine rIL-4 (9).  The purity in this fraction was ~85-90% as determined by band 
densitometry using Image J software (lanes 5 of Figure E5A). Expression and purification using 
empty pAP01 vector (with no IL-4 cDNA inserted) did not produce equivalent bands of this size. 
Western blot analysis using anti-IL-4 antibodies produced a similarly sized band confirming that 
this protein was indeed IL-4 (Figure E5B). The expected protein size and reactivity to anti-IL-4 
antibody provides sufficient evidence to confirm the identity of hrIL-4. 
 
Bioactivity of hrIL-4 was assessed by its effect on T-cell proliferation and CD23 expression on 
B-cells. Addition of hrIL-4 induced T-cell proliferation in a dose-dependent manner (179% at 
5ng/ml rIL-4 (p=0.03), 398% at 20ng/ml rIL-4 (p=0.002) and 522% at 100ng/ml rIL-4 (p=0.001) 
compared to the negative control; Figure E5C) while the subsequent addition of neutralizing IL-4 
antibody (at 0.5, 5 and 20μg/ml) suppressed this observed hrIL-4-induced proliferation 
(suppression at 20ng/ml hrIL-4 was 54%, 71% (p=0.04) and 76% (p=0.04); suppression at 
100ng/ml was 22%, 62% (p=0.02), 69% (p=0.02), respectively). Similarly, there was a dose-
dependent induction of CD23 (a low affinity IgE receptor) expression on B-cells (CD3
-CD19+) 
when hrIL-4 was added at different concentrations. The median CD23 frequency [IQR], 
expressed as a % of B-cells, was 25.6% [10.7-41.1] at 0.5ng/ml (p=0.005), 50.2% [30.5-64.2] at 
5ng/ml (p=0.002) and 64.6 [56.8-69.7] at 50ng/ml of hrIL-4 (p=0.001; Figure E5E). 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
E1. Dheda K, Chang JS, Breen RA, Kim LU, Haddock JA, Huggett JF, Johnson MA, Rook 
GA, Zumla A. In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary 
tuberculosis. American journal of respiratory and critical care medicine 2005;172:501-508. 
E2. Roberts T, Beyers N, Aguirre A, Walzl G. Immunosuppression during active tuberculosis 
is characterized by decreased interferon- gamma production and cd25 expression with elevated 
forkhead box p3, transforming growth factor- beta , and interleukin-4 mrna levels. The Journal 
of infectious diseases 2007;195:870-878. 
E3. Wong ML, Medrano JF. Real-time pcr for mrna quantitation. BioTechniques 2005;39:75-
85. 
E4. Pfaffl MW, Hageleit M. Validities of mrna quantification using recombinant rna and 
recombinant DNA external calibration curves in real-time rt-pcr. Biotechnology Letters 
2001;23:275-282. 
E5. Hou Y, Zhang H, Miranda L, Lin S. Serious overestimation in quantitative pcr by circular 
(supercoiled) plasmid standard: Microalgal pcna as the model gene. PLoS ONE 2010;5:e9545. 
E6. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Validation of 
housekeeping genes for normalizing rna expression in real-time pcr. BioTechniques 
2004;37:112-114, 116, 118-119. 
E7. Siawaya JF, Bapela NB, Ronacher K, Beyers N, van Helden P, Walzl G. Differential 
expression of interleukin-4 (il-4) and il-4 delta 2 mrna, but not transforming growth factor beta 
(tgf-beta), tgf-beta rii, foxp3, gamma interferon, t-bet, or gata-3 mrna, in patients with fast and 
slow responses to antituberculosis treatment. Clin Vaccine Immunol 2008;15:1165-1170. 
E8. Zhao Y, Chapman DA, Jones IM. Improving baculovirus recombination. Nucleic acids 
research 2003;31:E6-6. 
E9. Nuntaprasert A, Mori Y, Fujita K, Yoneda M, Miura R, Tsukiyama-Kohara K, Kai C. 
Expression and purification of recombinant swine interleukin-4. Comparative immunology, 
microbiology and infectious diseases 2005;28:17-35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES 
 
Table E1: Primer and probe sequences to determine cytokine mRNA levels by quantitative real-
time PCR.  
Gene of Interest 
(NCBI Accession 
numbers) 
Sequence 
○ Forward primer 5’ - 3’ 
● Reverse primer 5 ’- 3’ 
◊ Probe 5’- 6-FAM/ZEN/IOWA BLACK FQ - 3’ 
Tm 
(oC) 
Product 
size (bp) 
HuPO 
(NM_001002.3) 
 
○ GCTTCCTGGAGGGTGTCC 
● GGACTCGTTTGTACCCGTTG 
◊ TGCCAGTGT/ZEN/CTGTCTGCAGATTGG 
58.0 
55.9 
61.3 
106 
IFN-γ 
(NM_000619.2) 
○ TTCAGCTCTGCATCGTTTTG 
● TCCGCTACATCTGAATGACCT 
◊ TGGCTGTTA/ZEN/CTGCCAGGACCCA 
53.7 
55.6 
63.0 
112 
IL-4 
(NM_000589.3) 
○ GCTGCCTCCAAGAACACAAC 
● TGTAGAACTGCCGGAGCAC 
◊ AAACCTTCT/ZEN/GCAGGGCTGCGAC 
56.8 
57.3 
62.5 
71 
IL-4δ2 
(NM_172348.2) 
○ CCTCACAGAGCAGAAGAACAC 
● TGTAGAACTGCCGGAGCAC 
◊ AAACCTTCT/ZEN/GCAGGGCTGCGAC 
55.4 
57.3 
62.5 
74 
 
 
 
 
 
 
 
 
Table E2. Cloning primers used to amplify cDNA regions containing the qPCR targets of interest 
for IFN-γ and HuPO. The amplified regions were used to generate the plasmid standards. 
 
Gene of Interest 
 
Sequence 
○ Forward cloning primer 5’ - 3’ 
● Reverse  cloning primer 5 ’- 3’ 
Tm 
(oC) 
HuPO 
(NM_001002.3) 
○ TTCGACAATGGCAGCATCTACAACC 
● AAGGTGTAATCCGTCTCCACAGAC 
59.5 
58.3 
IFN-γ 
(NM_000619.2) 
○ TTGGCTTAATTCTCTCGGAAACGATG 
● AGAGTTCCATTATCCGCTACATCTG 
57.3 
56.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table E3. Details of experimental setup including cell numbers and stimulant concentrations in the 
mycobacterial containment assay to determine the effect of IL-4 on mycobacterial containment. 
 
Condition 
DAY 1 
DAY 6 
MDMs PBMCs 
cell 
number 
cell 
number 
Stimulant 
Cells co-
cultured with 
infected 
MDMs 
PPD 
(μg/ml) 
hrIL-4 
(ng/ml) 
anti-
IL-4 
Abs 
(μg/ml) 
anti-IL-
4R Abs 
(μg/ml) 
c
o
n
tr
o
ls
 H37Rv infected 
MDMs only 
2x105 - - - - - - 
PPD Teff 2x10
5 2x105 12 - - - PPD Teff 
in
te
rv
e
n
ti
o
n
s PPD+IL-4 Teff 2x10
5 2x105 12 
5, 20 & 
100 
- - PPD+IL4 Teff 
IL-4 neutralization 2x105 2x105 12 
20 &   
100 
20 - PPD+IL4 Teff 
IL-4 receptor 
neutralization 
2x105 2x105 12 
20 &   
100 
- 10 PPD+IL4 Teff 
 
 
 
 
 
 
 
 
 
 
 
Table E4. Details of experimental setup including cell numbers and stimulant concentrations in the 
mycobacterial containment assay to determine the mechanisms involved in the IL-4 associated 
modulation of mycobacterial containment by flow cytometry. 
 
Condition 
DAY 1 
DAY 6 
MDMs PBMCs 
cell 
number 
cell 
number 
Stimulant 
Cells co-
cultured with 
infected 
MDMs 
PPD 
(μg/ml) 
hrIL-4 
(ng/ml) 
anti-
IL-4 
Abs 
(μg/ml) 
anti-
IL-4R 
Abs 
(μg/ml) 
c
o
n
tr
o
ls
 H37Rv infected 
MDMs only 
6x105 - - - - - - 
PPD Teff 6x10
5 6x105 12 - - - PPD Teff 
in
te
rv
e
n
ti
o
n
s PPD+IL-4 Teff 6x10
5 6x105 12 
20 & 
100 
- - PPD+IL4 Teff 
IL-4 neutralization 6x105 6x105 12 100 20 - PPD+IL4 Teff 
IL-4 receptor 
neutralization 
6x105 6x105 12 100 - 10 PPD+IL4 Teff 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table E5: Comparison of colony forming units (CFU/ml) and % mycobacterial containment in the 
control and IL-4 interventions wells in the M.tb containment assay. Statistical analysis between the 
TB and LTBI groups were performed using Mann-Whitney test. 
Group 
Outcome 
measure 
Controls Interventions 
H37Rv 
infected 
MDMs 
PPD Teff PPD+IL4 
Teff (5ng/ml 
IL-4) 
PPD+IL4 Teff 
(5ng/ml IL-4) 
PPD+IL4 Teff 
(100ng/ml IL-4) 
TB 
CFU/ml; median 
[IQR] 
30.7x103  
[6.5; 88.8] 
15.7x103 
[3.8; 60.4] 
29.1x103 
[6.8; 91.6] 
42.6x103 
[7.7; 92.7] 
43.8x103 
[8.5; 127.9] 
% M.tb 
containment 
[IQR] 
- 
46% 
[12; 60] 
1%  
[-49; 34] 
-73% 
[-167; 1] 
-33% 
[-96; -17]  
LTBI 
CFU/ml; median 
[IQR] 
101.7x103 
[41.3 - 217.0] 
28.0x103 
[16.6; 79.7] 
45.6x103 
[29.2; 190.0] 
70.0x103 
[49.6; 180.0] 
108.3x103 
[62.2; 232.0] 
% M.tb 
containment 
[IQR] 
- 
72% 
[28; 77] 
64% 
[-144; 71] 
18% 
[-88; 41] 
-6% 
[-229; 42] 
*p-value - 0.22 0.61 0.27 0.43 
*p-value for comparison between % Mtb containment between LTBI and TB group using Mann Whitney 
test 
 
 
 
 
 
 
 
 
Table E6. Median frequency of regulatory T-cell (Tregs) expressing IL-10 in cells of the 
mycobacterial containment assay. Values are expressed as the median % of CD4+CD25+FoxP3+ Tregs 
and interquartile range in parentheses (IQR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte 
 
Infected MDMs 
+ 
PPD Teff PPD+IL-4 Teff 
(20ng/ml) 
PPD+IL-4 Teff 
(100ng/ml) 
 
% Tregs expressing  
IL-10  
Median % (IQR) 
 
3.3 
 (0.5-24.5) 
4.6 
 (1.6-13.6) 
1.1 
 (0.6-11.4) 
FIGURES 
 
 
Figure E1. Melt curve analysis to determine IL-4 quantitative PCR primer sequence specificity 
using Rotor Gene Q software. 
 
 
 
  
 
Figure E2. Generation of IL-4 standard curve to determine unknown values by absolute 
quantification method using Rotor-Gene Q software. Serial 10-fold dilutions of IL-4 plasmids 
standard (blue) and 2 unknown samples (red) were amplified in a quantitative PCR assay. No reverse 
transcriptase (no RT; green) controls and no template controls (NTC; black) and were also included. The 
fluorescence plot (top) was used to generate the standard curve (bottom right). PCR efficiency was 100% 
and R2 value was 0.9995 for this assay. The calculated copy numbers (Calc conc) for the samples (red), 
no RT control (Green) and NTC (black) derived from the standard curve are shown in the adjacent table. 
The variance (%Var) for individual standards was <22% and coefficient of variance (intra-assay 
variation) for each dilution was <20%. Both controls did not have any detectable copies.  
 
 
 
 
 
 
 
 
 
  
Figure E3. Inter-assay variability in (A) copy number and (B) Ct value of a quantitative PCR 
(qPCR) assay to determine IL-4 plasmid standard copy number. qPCR amplification was performed 
on serial 10-fold dilution (106-101) of linearized IL-4 plasmid standard in five separate runs. Each circle 
represents a single experiment. In (A) the x-axis show the expected copy numbers and the left y-axis 
show the expected copy numbers while the right y-axis shows the % PCR efficiency. In (B), the x-axis 
show the expected copy numbers and the y-axis show CT values. Lines and error bars represent mean 
values and 95% confidence intervals, respectively. In (A), the coefficient of variance at each dilution and 
for PCR efficiency (mean 100.0; 95% CI 96.1-103.9) was <10%.  
 Figure E4. mRNA expression levels of A) IFN-γ B) IL-4 and the cytokine expression ratio of C) IL-
4\IFN-γ in cells of broncho-alveolar lavage (BAL) and peripheral whole blood (Blood) from 
matched patients with pulmonary tuberculosis (TB; n=5) and presumed latently infected controls 
(LTBI; n=4) measured using a validated quantitative real-time PCR assay. Data is shown on a log10 
scale and copy numbers are expressed per million copies of HuPO (validated reference gene). Statistical 
analyses between groups were performed using the Mann-Whitney test and p<0.05 was deemed 
significant.  
  
Figure E5. mRNA expression levels of (A) IFN-γ (B) IL-4 and (C) IFN-γ:IL-4 ratio stratified by 
sputum smear status in peripheral whole blood from patients with pulmonary tuberculosis (TB; 
Blood n=23) as measured by quantitative real-time PCR. Data is shown on a log10 scale and copy 
numbers are expressed per million copies of HuPO. Statistical analyses were performed using the Mann-
Whitney test and p<0.05 was deemed significant 
 
 
  Figure E6: Measurement of IL-4 protein in broncho-alveolar lavage and peripheral blood mononuclear 
cell culture supernatants from TB patients and LTBI controls. 
 
 
 
 
 
 
  
Figure E7: Measurement of IL-13 protein in broncho-alveolar lavage and peripheral blood mononuclear 
TB-antigen stimulated cell culture supernatants from TB patients and LTBI controls.  
 
  
Boxed – start and stop codons 
Exon 1 of IL-4 
Exon2 of IL-4 
Exon 3 of IL-4 
Exon 4 of IL-4 
Decahistidine tag 
Restriction enzyme sites 
 
1      GGAACGGCTC CGCCCACTAT TAATGAAATT AAAAATTCCA ATTTTAAAAA ACGCAGCAAG 
61     AGAAACATTT GTATGAAAGA ATGCGTAGAA GGAAAGAAAA ATGTCGTCGA CATGCTGAAC 
121    AACAAGATTA ATATGCCTCC GTGTATAAAA AAAATATTGA ACGATTTGAA AGAAAACAAT 
181    GTACCGCGCG GCGGTATGTA CAGGAAGAGG TTTATACTAA ACTGTTACAT TGCAAACGTG 
241    GTTTCGTGTG CCAAGTGTGA AAACCGATGT TTAATCAAGG CTCTGACGCA TTTCTACAAC 
301    CACGACTCCA AGTGTGTGGG TGAAGTCATG CATCTTTTAA TCAAATCCCA AGATGTGTAT 
361    AAACCACCAA ACTGCCAAAA AATGAAAACT GTCGACAAGC TCTGTCCGTT TGCTGGCAAC 
421    TGCAAGGGTC TCAATCCTAT TTGTAATTAT TGAATAATAA AACAATTATA AATGCTAAAT 
481    TTGTTTTTTA TTAACGATAC AAACCAAACG CAACAAGAAC ATTTGTAGTA TTATCTATAA 
541    TTGAAAACGC GTAGTTATAA TCGCTGAGGT AATATTTAAA ATCATTTTCA AATGATTCAC 
601    AGTTAATTTG CGACAATATA ATTTTATTTT CACATAAACT AGACGCCTTG TCGTCTTCTT 
661    CTTCGTATTC CTTCTCTTTT TCATTTTTCT CTTCATAAAA ATTAACATAG TTATTATCGT 
721    ATCCATATAT GTATCTATCG TATAGAGTAA ATTTTTTGTT GTCATAAATA TATATGTCTT 
781    TTTTAATGGG GTGTATAGTA CCGCTGCGCA TAGTTTTTCT GTAATTTACA ACAGTGCTAT 
841    TTTCTGGTAG TTCTTCGGAG TGTGTTGCTT TAATTATTAA ATTTATATAA TCAATGAATT 
901    TGGGATCGTC GGTTTTGTAC AATATGTTGC CGGCATAGTA CGCAGCTTCT TCTAGTTCAA 
961    TTACACCATT TTTTAGCAGC ACCGGATTAA CATAACTTTC CAAAATGTTG TACGAACCGT 
1021   TAAACAAAAA CAGTTCACCT CCCTTTTCTA TACTATTGTC TGCGAGCAGT TGTTTGTTGT 
1081   TAAAAATAAC AGCCATTGTA ATGAGACGCA CAAACTAATA TCACAAACTG GAAATGTCTA 
1141   TCAATATATA GTTGCTGATC AGATCTGATC ATGGAGATAA TTAAAATGAT AACCATCTCG 
1201   CAAATAAATA AGTATTTTAC TGTTTTCGTA ACAGTTTTGT AATAAAAAAA CCTATAAATA 
1261   TAAAGCTTGG ATCCATGGGT CTCACCTCCC AACTGCTTCC CCCTCTGTTC TTCCTGCTGG 
1321   CATGTGCCGG CAACTTTGTC CACGGACACA AGTGCGATAT CACCTTACAG GAGATCATCA 
1381   AAACTTTGAA CAGCCTCACA GAGCAGAAGA CTCTGTGCAC CGAGTTGACC GTAACAGACA 
1441   TCTTTGCTGC CTCCAAGAAC ACAACTGAGA AGGAAACCTT CTGCAGGGCT GCGACTGTGC 
1501   TCCGGCAGTT CTACAGCCAC CATGAGAAGG ACACTCGCTG CCTGGGTGCG ACTGCACAGC 
1561   AGTTCCACAG GCACAAGCAG CTGATCCGAT TCCTGAAACG GCTCGACAGG AACCTCTGGG 
1621   GCCTGGCGGG CTTGAATTCC TGTCCTGTGA AGGAAGCCAA CCAGAGTACG TTGGAAAACT 
1681   TCTTGGAAAG GCTAAAGACG ATCATGAGAG AGAAATATTC AAAGTGTTCG AGCGAAAACC 
1741   TGTATTTTCA GGGTACCCAC CATCACCATC ACCATCACCA TCACCATTAG CCTAGGTAGC 
1801   TGAGCGCATG CAAGCTGATC CGGGTTATTA GTACATTTAT TAAGCGCTAG ATTCTGTGCG 
1861   TTGTTGATTT ACAGACAATT GTTGTACGTA TTTTAATAAT TCATTAAATT TATAATCTTT 
1921   AGGGTGGTAT GTTAGAGCGA AAATCAAATG ATTTTCAGCG TCTTTATATC TGAATTTAAA 
1981   TATTAAATCC TCAATAGATT TGTAAAATAG GTTTCGATTA GTTTCAAACA AGGGTTGTTT 
2041   TTCCGAACCG ATGGCTGGAC TATCTAATGG ATTTTCGCTC AACGCCACAA AACTTGCCAA 
2101   ATCTTGTAGC AGCAATCTAG CTTTGTCGAT ATTCGTTTGT GTTTTGTTTT GTAATAAAGG 
2161   TTCGACGTCG TTCAAAATAT TATGCGCTTT TGTATTTCTT TCATCACTGT CGTTAGTGTA 
2221   CAATTGACTC GACGTAAACA CGTTAAATAG AGCTTGGACA TATTTAACAT CGGGCGTGTT 
2281   AGCTTTATTA GGCCGATTAT CGTCGTCGTC CCAACCCTCG TCGTTAGAAG TTGCTTCCGA 
2341   AGACGATTTT GCCATAGCCA CACGACGCCT ATTAATTGTG TCGGCTAACA CGTCCGCGAT 
2401   CAAATTTGTA GTTGAGCTTT TTGGAATTAT TTCTGATTGC GGGCGTTTTT GGGCGGGTTT 
2461   CAATCTAACT GTGCCCGATT TTAATTCAGA CAACACGTTA GAAAGCGATG GTGCAGGCGG 
2521   TGGTAACATT TCAGACGGCA AATCTACTAA TGGCGGCGGT GGTGGAGCTG ATGATAAATC 
2581   TACCATCGGT GGAGGCGCAG GCGGGGCTGG CGGCGGAGGC GGAGGCGGAG GTGGTGGCGG 
2641   TGATGCAGAC GGCGGTTTAG GCTCAAATGT CTCTTTAGGC AACACAGTCG GCACCTCAAC 
2701   TATTGTACTG GTTTCGGGCG CCGTTTTTGG TTTGACCGGT CTGAGACGAG TGCGATTTTT 
2761   TTCGTTTCTA ATAGCTTCCA ACAATTGTTG TCTGTCGTCT AAAGGTGCAG CGGGTTGAGG 
2821   TTCCGTCGGC ATTGGTGGAG CGGGCGGCAA TTCAGACATC GATGGTGGTG GTGGTGGTGG 
2881   AGGCGCTGGA ATGTTAGGCA CGGGAGAAGG TGGTGGCGGC GGTGCCGCCG GTATAATTTG 
2941   TTCTGGTTTA GTTTGTTCGC GCACGATTGT GGGCACCGGC GCAGGCGCCG CTGGCTGCAC 
3001   AACGGAAGGT CGTCTGCTTC GAGGCAGCGC TTGGGGTGGT GGCAATTCAA TATTATAATT 
3061   GGAATACAAA TCGTAAAAAT CTGCTATAAG CATTGTAATT TCGCTATCGT TTACCGTGCC 
3121   GATATTTAAC AACCGCTCAA TGTAAGCAAT TGTATTGTAA AGAGATTGTC TCAAGCTCGG 
3181   ATCGATCCCG CACGCCGATA ACAAGCCTTT TCATTTTTAC TACAGCATTG TAGTGGCGAG 
3241   ACACTTCGCT GTCGTCGAGG TTTAAACGCT TCCTCGCTCA CTGACTCGCT GCGCTCGGTC 
3301   GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT ATCCACAGAA 
3361   TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC AGCAAAAGGC CAGGAACCGT 
3421   AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA GCATCACAAA 
3481   AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT 
3541   CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG 
3601   TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCATA GCTCACGCTG TAGGTATCTC 
3661   AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC ACGAACCCCC CGTTCAGCCC 
3721   GACCGCTGCG CCTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGTAAG ACACGACTTA 
3781   TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT 
3841   ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT ATTTGGTATC 
3901   TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA 
3961   CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC AGCAGATTAC GCGCAGAAAA 
4021   AAAGGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGGT CTGACGCTCA GTGGAACGAA 
4081   AACTCACGTT AAGGGATTTT GGTCATGAGA TTATCAAAAA GGATCTTCAC CTAGATCCTT 
4141   TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC TTGGTCTGAC 
4201   AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT TCGTTCATCC 
4261   ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC GGGAGGGCTT ACCATCTGGC 
4321   CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG CTCCAGATTT ATCAGCAATA 
4381   AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC CGCCTCCATC 
4441   CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC 
4501   AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG TATGGCTTCA 
4561   TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCCATGTT GTGCAAAAAA 
4621   GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC AGTGTTATCA 
4681   CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT AAGATGCTTT 
4741   TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG GCGACCGAGT 
4801   TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG 
4861   CTCATCATTG GAAAACGTTC TTCGGGGCGA AAACTCTCAA GGATCTTACC GCTGTTGAGA 
4921   TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT CAGCATCTTT TACTTTCACC 
4981   AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAAGGG AATAAGGGCG 
5041   ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG CATTTATCAG 
5101   GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA ACAAATAGGG 
5161   GTTCCGCGCA CATTTCCCCG AAAAGTGCCA CCTGACGCGC CCTGTAGCGG CGCATTAAGC 
5221   GCGGCGGGTG TGGTGGTTAC GCGCAGCGTG ACCGCTACAC TTGCCAGCGC CCTAGCGCCC 
5281   GCTCCTTTCG CTTTCTTCCC TTCCTTTCTC GCCACGTTCG CCGGCTTTCC CCGTCAAGCT 
5341   CTAAATCGGG GGCTCCCTTT AGGGTTCCGA TTTAGTGCTT TACGGCACCT CGACCCCAAA 
5401   AAACTTGATT AGGGTGATGG TTCACGTAGT GGGCCATCGC CCTGATAGAC GGTTTTTCGC 
5461   CCTTTGACGT TGGAGTCCAC GTTCTTTAAT AGTGGACTCT TGTTCCAAAC TGGAACAACA 
5521   CTCAACCCTA TCTCGGTCTA TTCTTTTGAT TTATAAGGGA TTTTGCCGAT TTCGGCCTAT 
5581   TGGTTAAAAA ATGAGCTGAT TTAACAAAAA TTTAACGCGA ATTTTAACAA AATATTAACG 
5641   TTTACAATTT CCCATTCGCC ATTCAGGCTG CGCAACTGTT GGGAAGGGCG ATCGGTGCGG 
5701   GCCTCTTCGC TATTACGCCA 
 
Figure E8. The full nucleotide sequence of the bacmid transfer vector containing IL-4, pAP01-IL4 -
His (5720bp), used to express human recombinant IL-4. The start and stop codons, the IL-4 sequence, 
decahistidine tag and restriction sites used for insertion of the IL-4 cDNA sequence are also shown are all 
annotated  
 
 
 
 
 
Figure E9. Expression, purification and bioactivity of human recombinant IL-4 (hrIL-4). hrIL-4 was 
expressed using a baculovirus expression system and purified using Ni2+ affinity columns. (A) a 15% 
sodium-dodecyl-sulfate-polyacrylamide-gel-electrophoresis (SDS-PAGE) gel of hrIL-4 purification 
fractions  showing (1) post-infection Sf21 insect cell supernatant (2) flow-through after column binding 
(3) 1st wash with 50mM imidazole (4) 2nd wash with 50mM imidazole (5) elution of rIL-4 at 500mM 
imidazole. The eluted protein had a size of ~17kDa (lane 5). (B) Western blot analysis of the purified 
hrIL-4 fraction probed with anti-IL4 antibody at 1:2500. Molecular weight markers are shown on the left 
in kiloDaltons (kDa) and 10-15μl of each fraction was loaded onto the gel. (C) hrIL-4 induces 
proliferation of T-cells pre-activated with anti-CD3 in peripheral blood mononuclear cells of healthy 
participants (n=6) in a concentration dependent manner. The addition of anti-IL-4 neutralization 
antibodies reduces the IL-4-mediated T-cell proliferation (n=3) also in a concentration dependent manner. 
Proliferation was measured in a 3H-Thymidine proliferation assay. hrIL4 induces expression of CD23 on 
B-cells (CD3+CD19+) in peripheral blood mononuclear cells of healthy participants (n=6) in a 
concentration dependent manner as measured by flow cytometry. The gating strategy for identification of 
CD3-CD19+CD23+ cells is shown in (D). The median frequency (%) and interquartile range of CD3-
CD19+CD23+ cells at different concentrations of rIL-4 are shown in (E). Statistical analysis was 
performed using the Wilcoxon matched-pairs signed rank test and p<0.05 was deemed significant. 
 
 
 Figure E10. The effect of human recombinant IL-4 on mycobacterial containment in infected 
monocyte-derived macrophages (MDMs) from healthy participants with latent TB infection (LTBI; 
n=5). A mycobacterial containment assay was performed where H37Rv-infected MDMs were cultured by 
themselves or co-cultured with peripheral blood mononuclear cells pre-primed with purified protein 
derivation alone (PPD Teff), or PPD and hrIL-4 (PPD+IL-4 Teff) at concentrations of 5, 20 and 100ng/ml 
hrIL-4. Results are expressed as (A) median colony forming units (CFU/ml) in TB patients and (B) The 
% mycobacterial (M.tb) containment, defined as the change in M.tb survival compared to the “H37Rv-
infected MDMs only” control, were also determined. Increased % M.tb containment indicates a reduction 
in M.tb survival whereas decreased % M.tb containment indicates an increase in M.tb survival. Statistical 
analysis was performed using the Wilcoxon matched-pairs signed rank test and p<0.05 was deemed 
significant. 
 
 
 
 
 
 
 
 
 
 
  
Figure E11. The effect of human recombinant IL-4 on Th1 cytokine expression in in macrophages 
in a mycobacterial containment assay as measured by flow cytometry. The % of CD14+CD16+ 
macrophages expressing (A) IFN-γ and (B) TNFα in cells harvested from a mycobacterial containment 
assay from pulmonary TB patients. H37Rv-infected MDMs were co-cultured with peripheral blood 
mononuclear cells pre-primed with purified protein derivation (PPD) alone (PPD Teff) or PPD and hrIL-4 
(PPD+IL-4 Teff) at concentrations of 20ng/ml (n=10) and 100ng/ml (n=16). Statistical analyses were 
performed using the Wilcoxon matched-pairs signed rank test between interventions and the Mann 
Whitney U test between CD4+ and CD8+ lymphocytes. A p-value<0.05 was deemed significant.  
 
 
 
 
 
 
 
 
 
Figure E12. The effect of blocking IL-4 receptor on mycobacterial containment and on cytokine 
and regulatory T-cell expression in a mycobacterial containment assay. H37Rv-infected MDMs were 
co-cultured with peripheral blood mononuclear cells pre-primed with PPD alone (PPD Teff) or PPD and 
hrIL-4 (PPD+IL-4 Teff) at 20 and 100ng/ml hrIL-4. To the IL-4 interventions, anti-IL4-receptor (IL-4R) 
antibody (10μg/ml) was added at the same time as hrIL-4 (day 1). In TB patients (n=2), mycobacterial 
containment was measured in terms of a) colony forming unit/ml (CFU/ml) and b) % mycobacterial 
(M.tb) containment, defined as the change in M.tb survival compared to the “H37Rv-infected MDMs 
only” control.  Increased % M.tb containment indicates a reduction M.tb survival whereas decreased % 
M.tb containment indicates an increase in M.tb survival. The % of CD4+ lymphocytes that were c) Treg 
(CD25+FoxP3+) and expressing d) IFN-γ were also determined within the system (cells co-cultured within 
the M.tb containment assay) by flow cytometry. In this case, IL-4R blocking was assessed using anti-IL-
4R antibodies (n=4; at 100ng/ml of IL-4).  Statistical analysis was performed using the Wilcoxon 
matched-pairs signed rank test and p<0.05 was deemed significant. 
 
 
